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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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Genotype	  ≠	  Phenotype	  
Environment	  maXers!	  
Ancestry	  maXers!	  
Genomic	  background	  maXers!	  
Longitudinal	  course	  maXers!	  
	  
We	  can	  only	  begin	  to	  really	  understand	  this	  if	  we	  u<lize	  the	  
power	  of	  intense	  networking	  via	  internet-­‐enabled	  archiving	  
and	  distribu<on	  of	  consumer	  owned	  and	  managed	  data.	  
Take	  Home	  Message	  
Categorical	  Thinking	  Misses	  Complexity	  
A	  conceptual	  model	  of	  canaliza:on.	  	  The	  y	  plane	  represents	  a	  phenotypic	  spectrum,	  the	  x	  
plane	  represents	  the	  canalized	  progression	  of	  development	  through	  <me,	  and	  the	  z	  plane	  
represents	  environmental	  fluctua<ons.	  	  	  
Expression	  Issues	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  
preXy	  much	  ALL	  muta<ons	  in	  humans,	  as	  we	  
have	  not	  systema<cally	  sequenced	  or	  
karyotyped	  any	  gene<c	  altera<on	  in	  
Thousands	  to	  Millions	  of	  randomly	  selected	  
people,	  nor	  categorized	  into	  ethnic	  classes,	  i.e.	  
clans.	  
Complexity	  
•  There	  are	  ~25-­‐100	  TRILLION	  cells	  in	  each	  
human	  body,	  with	  ~6	  billion	  nucleo<des	  per	  
cell.	  
•  There	  is	  extensive	  modifica<on	  of	  DNA,	  RNA	  
and	  proteins	  both	  spa<ally	  and	  temporally.	  
•  There	  are	  higher	  level	  mechanisms	  of	  soma<c	  
mosaicism,	  heterosis,	  and	  likely	  ancestral	  
inheritance.	  
A	  family	  in	  Utah,	  with	  a	  40	  year	  old	  Caucasian	  man	  
with	  
very	  severe	  obsessive	  compulsive	  disorder,	  severe	  
depression	  and	  intermiXent	  psychoses,	  with	  symptoms	  
that	  started	  around	  age	  5.	  
	  
Mul<ple	  medica<on	  trials	  failed	  over	  many	  years.	  	  
Considered	  treatment	  refractory.	  
	  
Humanitarian	  Device	  Exemp<on	  (HDE)	  
for	  OCD	  
Nucleus	  accumbens	  
Fig.	  1.	  Coronal	  sec<on	  of	  the	  brain	  near	  the	  nucleus	  accumbens	  with	  the	  track	  of	  
the	  electrodes	  on	  the	  leH	  and	  right	  side.	  
	  
2.5	  year	  follow-­‐up	  
Figure 2.   Yale Brown Obsessive Compulsive Scale (YBOCS) scores were measured 
for M.A  over a three year and seven months period of time.  A time series plot (A) 
shows a steady decline in YBOCS scores over the period of time spanning his DBS surgery 
(s) and treatment.   Incremental adjustments to neurostimulator voltage are plotted over a 
period of time following DBS surgery (A).  Mean YBOCS scores are plotted for sets of 
measurements taken before and after his Deep Brain Stimulation (DBS) surgery (B).  A 
one-tailed  unpaired  t  test  with  Welch’s  correction  results  in  a  p  value  of 
0.0056,  demonstrating  a significant difference  between YBOCS scores measured before 
and after the time of surgery.	
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Depleteable	  nature	  of	  baXery	  
•  BaXery	  replaced	  with	  a	  rechargeable	  baXery	  in	  January	  2012.	  
•  AHer	  the	  baXery	  was	  turned	  off	  the	  first	  <me,	  M.A.	  was	  not	  immediately	  under	  
any	  pain.	  	  However,	  aHer	  3	  days,	  M.A.	  almost	  aXempted	  suicide	  because	  of	  the	  
increase	  in	  depression,	  anxiety,	  and	  physical	  pain.	  	  Even	  worse,	  M.A.	  had	  liXle	  to	  no	  
insight	  into	  his	  disease,	  and	  had	  an	  increase	  in	  memory	  and	  congi<ve	  deficit	  and	  
had	  thus	  forgoXen	  the	  benefits	  that	  had	  been	  his	  just	  a	  few	  days	  prior.	  	  
•  M.A.	  decided	  to	  kill	  himself	  since	  he	  was	  unable	  to	  connect	  the	  renewal	  of	  
trauma<c	  symptoms	  with	  the	  baXery’s	  termina<on.	  	  Before	  gepng	  in	  his	  car	  to	  
end	  his	  life	  in	  another	  planned	  car	  wreck,	  M.A.	  saw	  his	  baXery	  modulator	  on	  the	  
front	  seat	  of	  his	  car.	  	  The	  modulator	  could	  turn	  his	  pacemaker	  on	  and	  off.	  	  When	  
M.A.	  saw	  it,	  he	  had	  a	  brief	  moment	  of	  clarity	  about	  feeling	  beXer	  in	  the	  past.	  	  
	  
•  Unsure	  if	  he	  was	  delusional	  or	  not,	  M.A.	  put	  the	  device	  up	  to	  his	  shoulder	  and	  
turned	  the	  baXery	  on.	  	  The	  change	  was	  instantaneous.	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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more significant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the field of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a significant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efficacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain findings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
specific variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular findings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneficial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactly con-
stitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or is
it the entire process from sample receipt through to the generation
and return of a report? Here, the legal definition is really quite
clear, as CLIA specifically states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performsnonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are specifi-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difficulties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation of
NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through th tate following s ccessful state certifi-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptabl
numbers of sp cimens for valid tion studies and guideli es for
stablishi g read dep , accuracy, sensitivity, tc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is defined by both the sequencing
and downstream informatics, and the informatics possibilities for a
standar equence are essentially limitless, how could CLIA supervi-
sion be applied to combined research and clinical genomics operations
without placi g an extreme regu atory burden on the sequencing
laboratory? Would every analysis type need to be certified, or would
a time-consuming standardized analysis be required even if it were
not needed for each p rticular peration?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The benefits of enacting such a split model could be substantial,
and we believe they could be gained without significantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually
Table 1
Processes involved in a CLIA-certified genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure m nual
2) Test systems, equipment, instrum nts, reagents, mat rials and
supplies
3) Establishment and verification of performance specifications
4) Maintenance and function checks
5) Calibration and calibration verification procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
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1.	  Sample	  Collec<on	  and	  handling	  
	  
	  
2.	  Sequencing/Analy<cs	  
	  
	  
3.	  Interpreta<on	  
“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characteris:cs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cer:fied,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administra:on.	  If	  you	  have	  
any	  ques:ons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informa:on,	  you	  should	  contact	  your	  doctor	  or	  a	  gene:c	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	  

Sample	  Collec<on	  and	  Handling	  	  
The	  Sample	  Collec<on	  kit	  includes	  barcoded	  collec<on	  tubes,	  a	  
Test	  Requisi<on	  form,	  an	  Informed	  Pa<ent	  Consent	  form,	  and	  a	  pre-­‐paid	  
shipping	  envelope.	  All	  paperwork	  must	  be	  completed	  and	  returned	  for	  
sample	  processing.	  Requests	  for	  Sample	  Collec<on	  kits	  must	  be	  
submiXed	  by	  a	  physician.	  
hXp://www.illumina.com/clinical/illumina_clinical_laboratory/igs_for_doctors/
how_to_order.ilmn	  
	  
Sequencing	  and	  Analy<cs	  
From	  the	  Illumina	  Understand	  
Your	  Genome	  Symposium	  
October	  2012	  
Evalua<on	  of	  344	  genes	  by	  Illumina	  
Refsum	  Disease?	  
•  Referred	  to	  optometry	  for	  further	  evalua<on	  
of	  this.	  
•  Found	  to	  have	  bilateral	  cataracts,	  large	  pupils,	  
and	  loss	  of	  night	  vision.	  
•  His	  mother	  and	  grandmother	  both	  have	  large	  
pupils	  and	  loss	  of	  night	  vision.	  No	  cataracts	  
known.	  


Table 1.  A summary of three clinically relevant genetic aberrations found in the clinical sequencing results of M.A.  
Mutations in MTHFR, BDNF,  and ChAT were found to be of potential clinical relevance for this person, as they are all implicated in 
contributing to the susceptibility and development of many neuropsychiatric disorders that resemble those present within M.A.  A 
brief summary of the characteristics of each mutation is shown, including the gene name, genomic coordinates, amino acid change, 
zygosity, mutation type, estimated population frequency and putative clinical significance. 
 
Gene name Genomic coordinates Amino acid change Zygosity Mutation type Population Frequency Clinical significance 
MTHFR chr1: 11854476 Glu>Ala heterozygous non-synon T:77% G:23% 
Susceptibility to psychoses, 
schizophrenia, occlusive vascular 
disease, neural tube defects, 
colon cancer, acute leukemia, and 
methylenetetra-hydrofolate 
reductase deficiency  
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% 
Susceptibility to OCD, psychosis, 
and diminished response to 
exposure therapy  
CHAT chr10: 50824117 Asp>Asn heterozygous non-synon G:85% A:15% 
Susceptibility to schizophrenia and 
other psychopathological 
disorders. 
   
No	  rare	  variants	  or	  CNVs	  with	  high	  biological	  effect	  as	  related	  to	  
mental	  illness.	  	  
	  
3	  common	  SNVs	  in	  this	  person	  that	  have	  been	  implicated	  in	  the	  
literatur 	  as	  predisposi g	  to	  mental	   llnes .	  

Pharmacogene<cs	  
  MA	  is	  homozygous	  for	  a	  p.Ile359Leu	  change	  in	  CYP2C9,	  and	  this	  variant	  has	  been	  
linked	  to	  a	  reduc<on	  in	  the	  enzyma<c	  ac<vity	  of	  CYP2C9,	  a	  member	  of	  the	  
cytochrome	  P450	  superfamily	  of	  enzymes.	  	  
	  
  Cytochrome	  P450	  proteins	  are	  mono-­‐oxygenases,	  which	  catalyze	  many	  reac<ons	  
associated	  with	  drug	  metabolism	  as	  well	  as	  reac<ons	  associated	  with	  the	  synthesis	  
of	  cholesterol,	  steroids	  and	  other	  lipids.	  	  
	  
  Fluoxe<ne	  is	  commonly	  used	  in	  the	  treatment	  of	  OCD;	  it	  has	  been	  shown	  to	  be	  as	  
effec<ve	  as	  clomipramine	  and	  causes	  less	  side	  effects.	  	  
  CYP2C9	  acts	  to	  convert	  fluoxe<ne	  to	  R-­‐norfluoxe<ne,	  and	  so	  MA	  may	  not	  be	  able	  
to	  adequately	  biotransform	  fluoxe<ne.	  
  It	  is	  notable	  that	  MA	  had	  no	  response	  to	  an	  80	  mg	  daily	  dose	  of	  fluoxe<ne.	  
  However,	  CYP2C9	  does	  not	  play	  a	  rate-­‐limi<ng	  role	  for	  other	  SSRIs	  or	  clomipramine	  


Utah,	  New	  York	  and	  Faroe	  Islands	  
Will	  results	  from	  my	  blood	  tests	  be	  forwarded	  to	  me?	  
	  
It	  will	  not	  be	  possible	  to	  give	  par:cipants	  results	  of	  the	  blood	  tests.	  Due	  to	  
regula<ons	  under	  the	  Clinical	  Laboratory	  Improvement	  Amendments	  (CLIA),	  we	  
are	  legally	  unable	  to	  return	  research	  results	  to	  par<cipants.	  Results	  from	  the	  
blood	  tests	  will	  not	  be	  placed	  in	  par<cipants'	  electronic	  health	  record.	  
Par<cipants	  should	  discuss	  any	  health	  concerns	  with	  their	  doctor	  or	  other	  health	  
care	  provider,	  who	  can	  arrange	  any	  necessary	  and	  appropriate	  tests.	  
	  
	   	   	   	   	   	   	  	  hXp://www.research.va.gov/mvp/veterans.cfm	  	  
	   	   	   	   	   	   	   	  accessed	  March	  6,	  2013	  
	  
	  
	  “A	  partnership	  is	  an	  arrangement	  where	  par<es	  agree	  to	  
cooperate	  to	  advance	  their	  mutual	  interests.”-­‐	  Wikipedia	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Dealing with the unexpected: consumer
responses to direct-access BRCA
mutation testing
Uta Francke1,2, Cheri Dijamco1, Amy K. Kiefer1, Nicholas Eriksson1,
Bianca MoiseV1, Joyce Y. Tung1, and Joanna L. Mountain1
1 23andMe, Inc., Mountain View, CA, USA
2 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
ABSTRACT
Background. Inherited BRCA gene mutations convey a high risk for breast and
ovarian cancer, but current guidelines limit BRCAmutation testing to women with
early-onset cancer and relatives of mutation-positive cases. Benefits and risks of
providing this information directly to consumers are unknown.
Methods. To assess and quantify emotional and behavioral reactions of consumers to
their 23andMe Personal Genome Service R  report of three BRCAmutations that are
common in Ashkenazi Jews, we invited all 136 BRCA1 and BRCA2mutation-positive
individuals in the 23andMe customer database who had chosen to view their BRCA
reports to participate in this IRB-approved study. We also invited 160 mutation-
negative customers who were matched for age, sex and ancestry. Semi-structured
phone interviews were completed for 32 mutation carriers, 16 women and 16 men,
and 31 non-carriers. Questions addressed personal and family history of cancer,
decision and timing of viewing the BRCA report, recollection of the result, emotional
responses, perception of personal cancer risk, information sharing, and actions taken
or planned.
Results. Eleven women and 14 men had received the unexpected result that they are
carriers of a BRCA1 185delAG or 5382insC, or BRCA2 6174delT mutation. None of
them reported extreme anxiety and four experiencedmoderate anxiety that was tran-
sitory. Remarkably, five women and sixmen described their response as neutral. Most
carrier women sought medical advice and four underwent risk-reducing procedures
after confirmatory mutation testing. Male carriers realized that their test results im-
plied genetic risk for female relatives, and several of them felt considerably burdened
by this fact. Sharing mutation information with family members led to screening
of at least 30 relatives and identification of 13 additional carriers. Non-carriers did
not report inappropriate actions, such as foregoing cancer screening. All but one
of the 32 mutation-positive participants appreciated learning their BRCAmutation
status.
Conclusions. Direct access to BRCA mutation tests, considered a model for
high-risk actionable genetic tests of proven clinical utility, provided clear
benefits to participants. The unexpected information demonstrated a cascade
eVect as relatives of newly identified carriers also sought testing and more
mutation carriers were identified. Given the absence of evidence for serious
emotional distress or inappropriate actions in this subset of mutation-positive
How to cite this article Francke U et al. (2013), Dealing with the unexpected: consumer responses to direct-access BRCAmutation
testing. PeerJ 1:e8; DOI 10.7717/peerj.8
204	  BRCA1	  (185delAG	  or	  5382i sC)	  or	  BRCA2	  6174delT	  
muta<on	  carriers	  (130	  males	   nd	  74	  femal s)	  in	  the	  23andMe	  
database	  of	  114,627	  customers	  who	  were	  at	  least	  18	  years	  of	  
age	  and	  had	  consented	  to	  par<cipate	  in	  research.	  	  
	  
Clinical	  Validity	  with	  “Worldwide	  Human	  
Gene:c	  Varia:on	  Database”	  and/or	  
“Medical	  Donor	  Informa:on	  Network”?	  
Pa:entsLikeMe	  
100,000	  Bri:sh	  Genomes	  
34 
•  Gives	  PGP/UYG	  sequencees	  full	  access	  to	  secure	  pla[orm	  for	  exploring	  and	  sharing	  genomes,	  	  
with	  each	  other	  and	  with	  full-­‐:me	  researchers,	  via	  Ingenuity	  Variant	  Analysis.	  
	  
•  Helps	  ci:zen-­‐scien:sts	  make	  their	  whole	  genomes	  at	  least	  modestly	  useful.	  
Today’s	  q	  not	  what	  my	  genome	  can	  do	  for	  me,	  but	  what	  our	  genomes	  can	  do	  for	  everyone.	  
	  
•  Leverages	  deep	  func:onal	  knowledge	  base	  &	  sensible	  comparison	  methods	  (e.g.,	  rare	  variant	  tests)	  
to	  give	  current	  data	  silos	  (PGP/hard	  drives)	  a	  working	  bakery	  for	  collabora<ve	  insight.	  
•  Sequencees	  retain	  full	  control	  &	  rights	  to	  their	  private	  data.	  
	  
•  Upcoming	  talk	  @	  ASHG	  (24	  October,	  9:15	  Grand	  Ballroom	  East)	  
Teaser:	  Includes	  preliminary	  collabora<ve	  findings	  on	  myopia	  in	  111	  whole	  genomes...	  
	  	  	  	  
•  Contact	  Nathan	  Pearson	  (npearson@ingenuity.com)	  for	  details	  
Proprietary and Confidential 
The	  Empowered	  Genome	  Cohort	  
Genotype	  ≠	  Phenotype	  
Environment	  maXers!	  
Ancestry	  maXers!	  
Genomic	  background	  maXers!	  
Longitudinal	  course	  maXers!	  
	  
We	  can	  only	  begin	  to	  really	  understand	  this	  if	  we	  u<lize	  the	  
power	  of	  intense	  networking	  via	  internet-­‐enabled	  archiving	  
and	  distribu<on	  of	  consumer	  owned	  and	  managed	  data.	  
Take	  Home	  Message	  
The	  End	  
RESEARCH Open Access
Low concordance of multiple variant-calling
pipelines: practical implications for exome and
genome sequencing
Jason O’Rawe1,2, Tao Jiang3, Guangqing Sun3, Yiyang Wu1,2, Wei Wang4, Jingchu Hu3, Paul Bodily5, Lifeng Tian6,
Hakon Hakonarson6, W Evan Johnson7, Zhi Wei4, Kai Wang8,9* and Gholson J Lyon1,2,9*
Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
* Correspondence: kaiwang@usc.edu; GholsonJLyon@gmail.com
1Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory,
One Bungtown Rd, Cold Spring Harbor, 11724, USA
8University of Southern California, 1501 San Pablo Street, Los Angeles, 90089,
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more significant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the field of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as tod y's DNA sequencing techn logy has the potent al to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a significant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efficacious pharmaceutical delivery. To this end, we need to de-
termine how to mov forward towards expanded clinical use of thi
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
Applied & Translational Genomics xxx (2013) xxx–xxx
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Circular RNAs Are the Predominant Transcript Isoform
from Hundreds of Human Genes in Diverse Cell Types
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Abstract
Most human pre-mRNAs are spliced into linear molecules that retain the exon order defined by the genomic sequence. By
deep sequencing of RNA from a variety of normal and malignant human cells, we found RNA transcripts from many human
genes in which the exons were arranged in a non-canonical order. Statistical estimates and biochemical assays provided
strong evidence that a substantial fraction of the spliced transcripts from hundreds of genes are circular RNAs. Our results
suggest that a non-canonical mode of RNA splicing, resulting in a circular RNA isoform, is a general feature of the gene
expression program in human cells.
Citation: Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO (2012) Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in
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Introduction
Deep sequencing of RNA from biological samples, ‘‘RNA-Seq’’,
is a powerful tool for discovering and cataloguing novel alterations
in the expression, sequence, and structure of transcriptomes. In the
present study, we used RNA-Seq in a deliberate search for
transcripts that could not be accounted for by conventional
splicing of primary transcripts from an unrearranged human
genome. Although our initial goal was to discover cancer-specific
chromosomal rearrangements by identifying the resulting fused or
rearranged transcripts, we also investigated the possibility that the
exon order specified by the genome sequence might be rearranged
during RNA processing. We were surprised to find numerous
examples of transcripts in which the exon order was a circular
permutation of the order encoded in the genome. We hypothe-
sized that these anomalous transcripts might the result of
intramolecular but non-canonical splicing events that joined a
splice donor to an upstream (i.e. toward the 59 end of the
transcript) splice acceptor to produce a circular RNA molecule.
Indeed, for many genes, in both cancer and normal human cells,
we found RNAs with circularly permuted exon orders at levels
comparable to those of the canonical, linear mRNA.
The first observation suggesting that eukaryotic RNAs can exist
in circular form was made more than 30 years ago by electron
microscopy [1]. 10 years later, human cytoplasmic RNA was
reported to contain very low levels of transcripts of the DCC gene
with exons spliced in non-canonical order (i.e. shuffled relative to
the reference genome). These scrambled transcripts were estimat-
ed to comprise less than one one-thousandth of DCC transcripts,
and the phenomenon was dubbed exon-scrambling [2]. Since that
time, a handful of expressed mammalian genes have been shown
to express circular RNA isoforms at low levels [3,4]. Such
examples include very low levels of human RNA transcripts with
scrambled exons observed in several human genes, including MLL
and ETS-1 [13,14].
The best-characterized circular transcripts are in rodents. The
mouse SRY gene, the sex-determining gene in males, consists of a
single exon. During development, the RNA exists as a linear
transcript that is translated into protein. In the adult testes, the
RNA exists primarily as a circular product that is predominantly
localized to the cytoplasm and is apparently not translated [5,6].
Studies have demonstrated that inverted repeats in the genomic
sequence flanking the SRY exon direct transcript circularization
[5,7,8]. The sodium transporter NCX1 and the rat cytochrome
P450 2C24 gene are two other well-studied examples of mouse
transcripts with circular isoforms that are expressed at relatively
low levels [9–11]. The circular isoform of the NCX1 gene is
thought to encode a protein, although this possibility has not been
conclusively demonstrated. Examples of exon scrambling have
also been found in Drosophila [12].
All examples of circular transcripts reported to date in humans
have been found to be expressed at low levels compared to the
dominant canonical linear isoform, requiring sensitive nested PCR
experiments for detection; these examples were discovered
inadvertently or in an effort to characterize the structure of
oncogenes. Circular RNAs have also been reported to be rare
isoforms of the human Cytochrome P-450 2C18, and dystrophin
transcripts [11,15]. Most recently, a circular isoform of the non-
coding RNA ANRIL was found to be expressed at very low levels;
its expression was correlated with INK4/ARF expression, and
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30733
